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Abstract
Background: Major issues in surgery for advanced ovarian cancer remain unresolved. Existing
treatment guidelines are supported by a few published reports and fewer prospective randomized
clinical trials.
Methods: We reviewed published reports on primary surgical treatment, surgical expertise,
inadequate primary surgery/quality assurance, neoadjuvant chemotherapy, interval debulking, and
surgical prognostic factors in advanced ovarian cancer to help resolve outstanding issues.
Results: The aim of primary surgery is a well-planned and complete intervention with optimal
staging and surgery. Surgical debulking is worthwhile as there are further effective treatments
available to control unresectable residual disease. Patients of gynecologic oncology specialist
surgeons have better survival rates. This may reflect a working 'culture' rather than better technical
skills. One major problem though, is that despite pleas to restrict surgery to experienced surgeons,
specialist centers are often left to cope with the results of inadequate primary surgical resections.
Patients with primary chemotherapy or those who have had suboptimal debulking may benefit from
interval debulking. A proposal for a better classification of residual tumor is given.
Conclusions:  Optimal surgical interventions have definite role to play in advanced ovarian
cancers. Improvements in surgical treatment in the general population will probably improve
patients' survival when coupled with improvements in current chemotherapeutic approaches.
Background
The Fédération Internationale de Gynécologie et
d'Obstétrigue (FIGO) classifies ovarian carcinoma in stage
I to IV [1,2]. Stage I has been defined as growth limited to
the ovaries; stage II as growth involving one or both ova-
ries with pelvic extension; stage III as tumor involving one
or both ovaries with peritoneal implants, and outside the
pelvis and/or positive retroperitoneal or inguinal nodes
and stage IV as having distant metastasis [1,2].
Tumors in stages I and II are generally considered to rep-
resent early disease, while stages III and IV evince late or
advanced disease [3,4]. The strong prognostic value of the
FIGO classification system has been proved in number of
studies [5].
Unfortunately, most ovarian carcinomas are detected only
when they are advanced. Results of studies evaluating
screening by tumor markers (a raised CA125 value) and/
or ultrasonography to detect early disease are not clear
[6,7]. Ultrasonography may become an increasingly
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important tool as it has been associated with higher detec-
tion rates in early stage disease and in patients with a
genetic predisposition to tumor [8-11]. However, use of
proteomics will perhaps identify more ovarian carcino-
mas at early stages in the future [12].
Though controversial till 70s, surgery is now recognized
an integral part of the treatment armamentarium in
advanced ovarian carcinoma. Aure et al., [13] presented
convincing evidence that extensive tumor removal
resulted in better survival even in advanced stage disease
and introduced the idea of primary tumor debulking sur-
gery. The value of primary debulking surgery was con-
firmed and its theoretical background was elucidated by
Griffith and Fuller [14]. Subsequent work showed that
debulking surgery improves an adverse vegetative func-
tion and nutritional problems such as loss of appetite and
nausea [15,16]. It was also suggested that primary debulk-
ing surgery removes therapy-resistant tumor cells and
increases the number of proliferating tumor cells (the
Gompertzian phenomenon), which makes these cells
more susceptible to subsequent chemotherapy [17-19].
These early hypotheses have partly been confirmed by the
finding of increased postoperative tumor proliferation
rates in patients after surgery [20].
Ongoing discussions about quality assurance and guide-
line-based therapy had helped to foster the impression
that the main issues in treating ovarian cancer have been
resolved and that the value of each procedure involved
has been supported by high levels of scientific evidence
[21-23]. Closer inspection reveals that it is not true. Only
a few treatment guidelines are supported by published
reports, and even fewer by prospective randomized clini-
cal trials. However, we strongly believe the value of retro-
spective studies is greatly underestimated. Recent analyses
show that the treatment effects assessed by observational
studies do not greatly differ in magnitude or quality from
those published in randomized, controlled trials [24,25].
Furthermore, biases created by the selection criteria inher-
ent in prospective randomized trials are frequently
ignored.
Thus, in this article we will concentrate on looking more
closely at several issues in surgical treatment, their effects
and importance in relation to outcome in advance ovar-
ian cancer.
Primary surgical treatment
The utility of primary surgery for advanced ovarian cancer
is well established. Its aim should be a well-planned,
extensive and complete intervention. Thus, no facility
should offer surgery for patients with ovarian cancer if
adequate standards of care cannot be met.
The optimal preparation of patients for surgery is very
important. Patients must be in a position to give fully
informed consent to any additional surgical procedures
found necessary during the operation. They should also
undergo colonic lavage, which will provide the surgeon
with better access to the lymph nodes and reduce risks in
cases where intestinal surgery is undertaken. Where cyto-
logical evaluation of peritoneal fluid aspired preopera-
tively, a raised concentration of serum CA125, or
ultrasound results indicate advanced malignancy, the
patient should be transferred to a specialist surgeon (see
below).
Many cases where the staging is not clear, laparoscopy
appears to be good tool for obtaining a definitive histo-
logical diagnosis in advanced ovarian cancer and helps in
planning the best surgical approach. Laparoscopic stag-
ing, in particular, can give a clear view of the extent of sur-
gery required and the difficulties that may be expected,
and it may be helpful in selecting patients for primary
(neoadjuvant) chemotherapy [26]. Video recording can
document the findings during laparoscopy and can be
used subsequently by the surgeon to plan optimal debulk-
ing surgery.
However, laparoscopic surgery of any suspicious adnexal
mass is not encouraged unless the risk of capsular rupture
and tumor spill is minimized by the use of endobags [27].
No cystic mass which is >10 cm in diameter and/or adher-
ent to the lateral pelvic wall should be removed laparo-
scopically [28].
The fear due to some in-vitro  and animal studies that
showed carbon dioxide pneumoperitoneum has adverse
effects on outcomes is probably unfounded, as a recent
analysis from second-look laparoscopies showed no
influence of pneumoperitoneum on overall survival [29].
Certainly, more data on this issue is required.
Since laparoscopy may increase tumor growth rates,
delays between laparoscopy and definitive surgery should
be avoided [30]. Although this view has not yet been sup-
ported by any other study, we believe that the time
between the suspected diagnosis of advanced ovarian can-
cer and surgery should be kept as short as possible. Delays
may result in a higher preoperative tumor mass which has
been identified as an adverse prognostic factor [31].
Surgical staging
Tumor stage is one of the primary prognostic factors.
Appropriate staging is vitally important for effective post-
operative therapeutic decision-making. Patients who have
been accurately staged as stage I may not require adjuvant
chemotherapy [32,33].World Journal of Surgical Oncology 2004, 2:32 http://www.wjso.com/content/2/1/32
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Requirements for appropriate staging after total abdomi-
nal hysterectomy and bilateral salpingo-oophorectomy
include multiple cytological washings, random biopsies
from the peritoneum and the diaphragm, omentectomy
and lymphadenectomy. The value of peritoneal cytology
is supported by prospective studies [34]. There are several
issues surrounding lymphadenectomy, and these are dis-
cussed later. In two studies, optimal staging resulted in
30% to 50% of the patients being reclassified to a higher
stage – a fact which has implications for subsequent treat-
ment [35,36]. A classification system for determining the
quality of surgical staging was introduced recently and is
shown in Table 1[33]. However, it may be only helpful for
comparisons of older studies since optimal staging is a
prerequisite of later therapeutic decisions.
Extent of surgery
In addition to the staging procedures mentioned earlier,
optimal surgical treatment for ovarian cancer comprises
tumor removal; removal of remaining ovaries, uterus, and
fallopian tubes, omentectomy, and radical para aortic and
pelvic lymphadenctomy [3,37]. The German national
treatment guidelines recommend a simultaneous appen-
dectomy and removal of the cul de sac over the perito-
neum of the small pelvis [38]. Since removal of all grossly
visible tumor is considered crucial for long-term survival,
surgery should be extended to include hemicolectomy,
splenectomy and stripping of the peritoneal reflection of
the diaphragm when the tumor masses infiltrate the entire
abdominal cavity, the colon, the diaphragm or other
structures respectively.
Although the reasoning behind performing these meas-
ures seems convincing, only lymphadenectomy has been
partly evaluated in a prospective, randomized trial. The
previously held belief that mere palpation of lymph nodes
is sufficient to gauge nodal status was refuted in this study
[39].
Lymphadenectomy plays a triple role in the treatment of
ovarian cancer. First, it is of diagnostic value since tumors
of apparently early stage show nodal involvement in
about 20% to 40% of the cases [40], If found positive, the
tumor must be classified as stage IIIc. Secondly, lym-
phadenectomy is of immense prognostic value. Most
importantly, lymphadenectomy may also have a thera-
peutic effect as retrospective studies comparing lym-
phadenectomy with no lymphadenectomy reported a
survival benefits with this procedure [41-43]. The data on
lymphadenectomy is however conflicting with one study
showing that the patients with stage III disease (tumor
residuals >2 cm) that has been debulked suboptimally do
not benefit from lymphadenectomy [44]. Other workers
report no benefit even if the residual tumor size is smaller
(1 cm) [45]. Though not fully published, the only pro-
spective, randomized trial shows that systematic lym-
phadenectomy did not result in better survival compared
to selective lymphadenectomy [46]. Mainly based on the
retrospective findings current views on treating stage III
disease suggest: systematic lymphadenectomy in cases of
residual tumors <1 cm, nodal debulking only where
tumors are larger than intra-abdominal residuals, and
nodal sampling in stage IV disease with pleural effusions
only [47].
To the best of our knowledge, there has been no study
testing the benefit of hysterectomy or omentectomy.
However, the concurrent incidence of endometrial carci-
noma in 10% to 25 % of patients, or its precursors in
about 30% to 50% of all ovarian cancers justifies this pro-
cedure [48,49].
Optimal debulking
Ovarian cancer is one of the tumors where surgical
debulking is considered worthwhile. This is due to availa-
bility of further effective treatments that are available to
control the unresectable residual disease. As early as 1934,
Meigs suggested that maximum cytoreductive surgery was
beneficial [50]. Many years later, in 1968, Munnell fol-
lowed this idea and proposed the idea of 'maximum sur-
gical effort' [51]. He distinguished between definitive
surgery, partial removal of the tumor and biopsy only.
Table 1: Surgical quality categories for staging of ovarian carcinomas (based on Trimbos et al. 2003)
Category of surgical quality Staging procedures included
Optimal - Inspection and palpation of all peritoneal surfaces; biopsies of any suspect lesion for metastasis; peritoneal 
washings; infra-colic omentectomy; blind biopsies of the right diaphragm and right and left para-colic gutter, pelvic 
side-walls of the ovarian fossa, of the bladder peritoneum and of the cul-de-sac and sampling of iliac and para-
aortic lymph nodes
Modified - Everything between optimal and minimal staging
Minimal - Inspection and palpation of all peritoneal surfaces and the retroperitoneal area; biopsies of any suspect lesions for 
metastasis; peritoneal washing; infracolic omentectomy
Inadequate - Less than minimal staging but at least careful inspection and palpation of all peritoneal surfaces and the 
retroperitoneal area; biopsies of any suspect lesion for metastasisWorld Journal of Surgical Oncology 2004, 2:32 http://www.wjso.com/content/2/1/32
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Since partial removal covers a wide range of interventions
that requires varying amount of efforts, optimal debulk-
ing was distinguished from suboptimal debulking.
Although there is no generally accepted definition, most
early studies considered a residual tumor size of <2 cm as
optimal [52]. In a more recent survey among gynecologi-
cal oncologists from United States of America (USA), 12%
of the responders defined optimal debulking surgery as no
visible tumor residuals, while 14% described it as residual
tumor masses less than 0.5 cm. However, 61% chose a 1
cm threshold and 13% considered a tumor of 1.5 cm to
2.0 cm as optimal [53]. Comparative analysis of diameters
of various residual diseases has shown that there exists
some sort of a threshold at 2 cm, above which no signifi-
cant differences in survival can be found. In contrast, sub-
set analyses of smaller diameters in residual disease show
improved patient prognosis [54]. This variation in the
interpretation of thresholds with prognostic impact calls
for a commonly accepted definition (see concluding
remarks) and more controlled trials, that need to be non-
randomized as it will not be ethically possible to leave
some tumor behind.
The results of an earlier meta analysis on cytoreductive
surgery might have been flawed not only due to absence
of clear definitions but also due to the combined effects of
subsequent chemotherapy [52]. In this study, the then
novel, platinum-containing chemotherapy had a stronger
impact on survival than cytoreductive surgery. A recent
and otherwise comparable meta analysis however, con-
firms the greater survival benefit of patients undergoing
maximum cytoreduction [55]. Another interesting study
stated that optimal cytoreduction means no visible resid-
ual tumor [31]. It has been further shown that the volume
of the residual tumor and the success of subsequent chem-
otherapy are interdependent [56].
Expertise of gynecological oncology surgeons
Based on available evidence it is generally accepted that
the experience and technical expertise of a surgeon are
important prognostic factors. Comparisons of overall sur-
vival in patients treated by gynecological oncology, gyne-
cologists and general surgeons have shown that patients
treated by surgeons trained in gynecology (gynecological
oncology) have a significantly better prognosis [57,58].
This finding may not reflect primarily on the technical
skills of these surgeons but rather reflection the 'environ-
ment' in which they work – where views and thoughts on
the biology of advanced tumors are freely shared and
patients are often treated by a team rather then individu-
als. As for surgeons there are only select patients with
uncommon neoplasms like gastrinomas, glucagonomas,
stomatostatinomas, and VIPomas, who profit from
debulking surgery with particular reference to prevent del-
eterious hormonal side-effects [59]. It is expected that new
chemotherapy and immunotherapeutical approaches will
probably lead to a re-evaluation of debulking surgery as a
complementary approach [60-62]. Till such time where
definite evidence is available, it is strongly recommended
that all patients should be treated by a gynec-oncologist.
There had been constant calls to regionalize specialist sur-
gery, however, no studies have yet shown better survival
in patients treated by 'high volume' operators or such spe-
cialists [63,64]. A recent study on quality control from
Hesse, Germany, showed striking deficiencies even at cen-
tral-referral hospitals [23]. Treatment by a multidiscipli-
nary team of specialists, has been shown to increase
patients' chances of survival without any disputes [65,66].
Patients probably benefit most from being treated in cent-
ers which promote excellent scientific exchange, and con-
tinuous education and self-evaluation among surgeons
besides providing multidisciplinary approach to
management.
Coping with inadequate primary surgery
Surgical treatment of advanced ovarian cancer is one of
the most demanding procedures in gynecological surgery.
Despite repeated requests to restrict surgery to experienced
surgeons, considerable numbers of patients are still oper-
ated by others. A population based study from Germany
showed that omentectomies were performed in about
50% of all cases of ovarian cancer and lymphadenectomy
were carried out only in 30% [22]. Another study from
USA showed that only about half of the patients receive
'standard' care [68]. In spite of the establishment of gyne-
cological oncology as a specialty in the USA, fewer than
half of the patients were originally seen by such a special-
ist [68]. More over the terminologies like "standard" are
not defined well.
The situation with regard to specialism depends strongly
on the medical infrastructure, and varies from country to
country and region to region. However, the problem of
inadequate primary surgery is real, and coping with it is a
frequent task in specialist centers even in developed coun-
tries. The question is what should be done for the patient
concerned? Interestingly, this is something that cannot be
found in textbooks [3,69,70]. Some of the literature sug-
gest re-laparotomy by experienced surgeons to achieve
reductions in all possible tumor mass [71,72] however,
there is no evidence to support this strategy.
In general, one of two situations occurs. First patients
present with no evidence of macroscopic tumor residuals
but staging procedures and/or operative measures were
omitted. Computed tomography (CT) or Magnetic reso-
nance imaging (MRI) to identify enlarged lymph nodes or
possible residual tumors in these situations may help to
decide on the need for second surgery. The belief that
tumor cells in retroperitoneal lymph nodes are better ableWorld Journal of Surgical Oncology 2004, 2:32 http://www.wjso.com/content/2/1/32
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to survive chemotherapy is supported by low cytotoxic
drug concentrations in these [73]. Therefore, it is reasona-
ble to consider enlarged lymph nodes as a decisive factor
favoring a direct surgical approach. It is interesting to note
that in endometrial carcinomas, a clinically negative
omentum was also found to be histologically negative in
most cases (sensitivity 89%) [74].
Patients with residual tumor mass have to be evaluated to
determine if it is possible to achieve no residual tumor or
microscopic residual tumor by immediate secondary sur-
gery. Although immediate laparotomy seems to be a good
idea, the limited capacity for surgery at specialist depart-
ments and delays in having the surgery are to be consid-
ered. The peritoneum shows inflammation shortly after
surgery reaching a high about 7 to 14 days afterwards [75].
Surgery at this time is considered far more complicated
and may result in higher blood loss and greater risk of
injury to neighboring abdominal organs [76]. However,
waiting for the inflammatory processes to resolve will give
the tumor further time to proliferate [20]. Therefore, inter-
val debulking surgery after three courses of chemotherapy
should be considered as an appropriate alternative.
Neoadjuvant chemotherapy
Disease spread >2 cm to the spleen, diaphragm, liver sur-
face, mesentery, or gallbladder is generally believed to be
inoperable. However, even these patients may often
undergo effective debulking procedures [26,77]. As men-
tioned earlier, laparoscopy can be used to reach decisions
on surgery. The only problem with laparoscopy in combi-
nation with neoadjuvant chemotherapy is a 30% rate of
port site metastasis, which is believed to be a result of the
pneumoperitoneum procedure created for laparoscopy
[78]. These metastases should be excised at the time of any
subsequent surgery [79].
An analysis of several retrospective studies on neoadju-
vant chemotherapy showed that there are no good rea-
sons to assume that this approach is associated with a
poorer prognosis [26]. The European Organisation for
Research and Treatment of Cancer (EORTC) protocol
55971 comparing upfront tumor debulking surgery with
neoadjuvant chemotherapy in patients with stage IIIc or
IV disease is accruing and its results will provide better
insights on this issue.
Interval tumor debulking
Interval debulking, is another approach to reduce tumor
burden between the cycles of chemotherapy. It has been
evaluated in two prospective randomized trials [80,81].
The EORTC study showed a clear survival advantage for
interval debulking (still noted in the 2001 update), the
Gynecologic Oncology Group (GOG-152) study has, as
yet, failed to show any benefit from interval debulking
[80,81]. Patients with residual tumor >1 cm received three
courses of cyclophosphamide/cisplatinum in the EORTC
study [80] or three courses of paclitaxel/cisplatinum in the
GOG-152 study. In both studies, patients who did not
respond to chemotherapy were removed from the study.
Those who responded were randomized to either second-
ary surgery or no surgery. Afterwards, all patients received
three more courses of the earlier chemotherapeutic
regimen.
Although there seem to be only minor differences in the
design of both trials, a closer look shows that in the GOG-
152 study, the number of stage IV patients was lower (6%)
compared with the EORTC (21%) study, the performance
status was better, and there was less residual tumor. This
was due to the eligibility criteria for GOG 152 which
stated that patients should have had surgery with maximal
effort to resect the uterus, tubes, ovaries, omentum, and
all gross residual ovarian cancer at the time of primary
surgery.
The questions about the benefit of interval debulking sur-
gery remain unresolved. However, it appears that patients
who have had neoadjuvant chemotherapy or suboptimal
debulking may profit from this treatment, while those
who have undergone primary, maximum effort surgery by
a gynecological oncologist are less likely to profit from it
[82].
Surgical prognostic factors
Size of the residual tumor, volume of the residual disease
and experience of the surgeon are important prognostic
factors [56,77]. Among these, only few can be influenced
by human intervention. Except for dose intensity of chem-
otherapy, recent literature indicates that the hemoglobin
concentrations before chemotherapy are of prognostic
value [83,84]. The latter may be influenced by the use of
erythropoietin which has shown positive effects on sur-
vival in cervical cancer [86].
As mentioned above, the frequently used definition of <2
cm for optimal debulking is arbitrary since every further
reduction in the size of residual tumor improves the prog-
nosis [54]. Thus, each threshold between 0 and 2 cm will
have its own prognostic relevance. While the criterion
'diameter of residual tumor' reflects tumor cell hypoxia
and reduces the pool of proliferating tumor cells suscepti-
ble to chemotherapy, the criterion 'residual tumor vol-
ume' alludes to the removal of therapy-resistant tumor
cells, which are believed to be responsible for early
recurrences. A comparison of both criteria in relation to
their prognostic impact has shown that residual tumor
volume is of greater importance [56]. As shown in sub-
group analyses of the intergroup trial confirming the
results of the GOG-111 study, a possibly superior chemo-World Journal of Surgical Oncology 2004, 2:32 http://www.wjso.com/content/2/1/32
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therapeutic regimen containing taxanes cannot compen-
sate for the tumor left behind after primary surgery [19].
Future trends
It is difficult to assess the future role of surgery in
advanced ovarian cancer. Neoadjuvant chemotherapy
may become more important. However, as the tumor
debulking surgery works, except in stage IV patients with
solid distant metastasis, it may be worth trying combined
ultrasound-guided laser interstitial thermotherapy for
non-resectable liver metastasis with conventional debulk-
ing surgery [87]. Apart from technical innovations, quality
control, quality assurance and documentation of patient
outcomes after surgery will probably play major parts in
treatment improvements.
Conclusion
Numerous studies have analyzed the effects of various
kind of chemotherapy in ovarian cancer. In contrast, only
a few prospective randomized studies have focused on
surgical issues in this type of tumor [46,80,81]. This lack
of surgical trials has probably contributed to inhomoge-
nous definitions regarding the terminology of surgical
interventions and surgical stages (early compared with
late) and the classification of operative success in general.
In future, we must aim to ensure that all patients are
treated along the generally accepted guidelines and
receive optimal debulking surgery which leaves only
microscopically detectable residual tumor as shown in
number of studies; it is certainly unethical at present to
evaluate this procedure in randomized clinical trials (see
Introduction). Other then this, there are many other rele-
vant issues which need to be resolved or clarified with spe-
cial reference to neoadjuvant chemotherapy, interval
debulking, the surgeon's training, and inadequate pri-
mary treatment. It would certainly be very helpful to dem-
onstrate clearly the consequences of what is supposed to
be an inadequate treatment.
The simple dichotomization of FIGO stages to early or late
does not correspond to any diagnostic, biological or ther-
apeutic advantage. We believe that it is far more reasona-
ble to consider stage I alone as early disease (perhaps even
only stage Ia and b), stages II and III (perhaps even stage
IV with pleural effusions) as intermediate disease, and
stage IV with organ metastasis as advanced disease. Such a
classification would follow current views on treatment,
since early ovarian carcinomas are treated primarily by
surgery (eventually fertility-sparing) and adjuvant chemo-
therapy in cases of increased risk, intermediate ones by
surgery and routine chemotherapy, and advanced disease
by chemotherapy only. Thus far, results of studies on stage
IV patients with organ metastases are inconsistent regard-
ing the benefit of surgery. This is another issue to be
resolved [88]. In this respect, FIGO may find subdividing
stage IV into stage IVa (pleural effusions) and IVb (organ
metastasis) worthwhile.
Disappointingly, the Tumor-Nodes-Metastasis (TNM)
classification follows the FIGO system and violates its
own principles by not accepting distant peritoneal metas-
tasis as a natural indicator of primary tumor size but also
by summarizing a nodal-positive disease stage as T3c (cor-
responding to FIGO IIIC) regardless of intra-abdominal
findings. This inconsistency has already created curious
confusions in current research. Nodal involvement has
been shown to impair prognosis, however, smaller intra-
abdominal tumors with nodal involvement (presented as
stage I to IIIb disease but, by definition, all stage IIIC)
show a significantly better prognosis than extensive intra-
abdominal tumor masses (again stage IIIC) [89].
Furthermore, residual disease should be properly defined.
The most rational approach is to regard microscopic resid-
uals as optimal. Case series claim that experienced gyne-
cologic-oncologic surgeons can clear up to 85% of
patients in the unfavorable subgroups (FIGO stage IIIc
and IV) of all visible tumor, leading to an extraordinarily
high five year survival rate of about 50% [77]. As dis-
cussed (see surgical prognostic factors), a good definition
of residual tumor would include aspects of both residual
tumor size and volume. A proposal is made in Table 2.
Table 2: Surgical documentation of residual tumor after debulking of ovarian carcinomas
Residual tumor status* Maximum diameter of residual tumor Maximum total volume of residual tumor
Optimal Microscopic No visible tumor
Minimal < 1 cm ≤ 10 cm3
Intermediate 1 – 2 cm > 10 cm3 but ≤ 100 cm3
Gross > 2 cm > 100 cm3
*To assign residual tumor to a certain status, both criteria, diameter and volume, have to be fulfilled. Otherwise the next lower category should be 
used.World Journal of Surgical Oncology 2004, 2:32 http://www.wjso.com/content/2/1/32
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In summary, more attention need be paid to surgery for
advanced ovarian cancer. These include necessary
improvements in treatment in the general population,
uniform definitions and terminology, and increasing
number of surgical clinical trials. Extrapolating from the
results of truly optimal ovarian cancer surgery, we believe
that improvements in surgery will lead to better patient
survival than improvements in current chemotherapeutic
approaches [55,90,91].
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